| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
56.72
|
|
2
|
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
50.94
|
|
3
|
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
41.47
|
|
4
|
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
26.95
|
|
5
|
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
11.32
|
|
6
|
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
|
JAMA
|
2013
|
10.43
|
|
7
|
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
|
Lancet
|
2015
|
7.99
|
|
8
|
Financial anatomy of biomedical research.
|
JAMA
|
2005
|
7.49
|
|
9
|
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.
|
Lancet
|
2015
|
6.13
|
|
10
|
The anatomy of health care in the United States.
|
JAMA
|
2013
|
2.58
|
|
11
|
NIH disease funding levels and burden of disease.
|
PLoS One
|
2011
|
2.56
|
|
12
|
Biomedical research in an age of austerity.
|
JAMA
|
2012
|
2.52
|
|
13
|
Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.
|
Med Care
|
2012
|
1.91
|
|
14
|
Pivotal studies of orphan drugs approved for neurological diseases.
|
Ann Neurol
|
2009
|
1.34
|
|
15
|
Local institutional review board (IRB) review of a multicenter trial: local costs without local context.
|
Ann Neurol
|
2010
|
1.23
|
|
16
|
Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.
|
Acad Pediatr
|
2012
|
1.15
|
|
17
|
Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study.
|
PLoS One
|
2012
|
1.14
|
|
18
|
Fear of health insurance loss among individuals at risk for Huntington disease.
|
Am J Med Genet A
|
2008
|
1.12
|
|
19
|
A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
|
Arch Neurol
|
2010
|
1.10
|
|
20
|
The past, present, and future of telemedicine for Parkinson's disease.
|
Mov Disord
|
2014
|
0.97
|
|
21
|
Telemedicine for the care of nursing home residents with Parkinson's disease.
|
Mov Disord
|
2009
|
0.93
|
|
22
|
Altered cholesterol and fatty acid metabolism in Huntington disease.
|
J Clin Lipidol
|
2010
|
0.88
|
|
23
|
Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.
|
Parkinsonism Relat Disord
|
2012
|
0.88
|
|
24
|
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
|
Psychiatr Serv
|
2013
|
0.86
|
|
25
|
Caring for the majority.
|
Mov Disord
|
2013
|
0.86
|
|
26
|
The benefits of exercise in Parkinson disease.
|
JAMA Neurol
|
2013
|
0.84
|
|
27
|
Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.
|
Trials
|
2014
|
0.83
|
|
28
|
Telemedicine in Leading US Neurology Departments.
|
Neurohospitalist
|
2012
|
0.83
|
|
29
|
Willingness of Parkinson's disease patients to participate in research using internet-based technology.
|
Telemed J E Health
|
2012
|
0.81
|
|
30
|
Opsoclonus-myoclonus syndrome and exaggerated startle response associated with small-cell lung cancer.
|
Mov Disord
|
2011
|
0.80
|
|
31
|
The return of the house call.
|
Ann Intern Med
|
2015
|
0.78
|
|
32
|
Web-based clinical assessments for Parkinson's disease: reliable and feasible.
|
Mov Disord
|
2012
|
0.76
|
|
33
|
Funding for biomedical research--reply.
|
JAMA
|
2013
|
0.75
|
|
34
|
Quality of life in epilepsy, multiple sclerosis, and beyond.
|
Ann Neurol
|
2007
|
0.75
|
|
35
|
Impact of alternative medical device approval processes on costs and health.
|
Clin Transl Sci
|
2014
|
0.75
|
|
36
|
Author Response.
|
Neurology
|
2015
|
0.75
|
|
37
|
Next Generation House Call.
|
Cerebrum
|
2017
|
0.75
|